At what pace is the anti-asthmatics and copd drugs market growing, and what is its estimated value?
The anti-asthmatics and COPD drugs market size has grown strongly in recent years. It will grow from $80.82 billion in 2024 to $86.11 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to include increased prevalence of respiratory diseases, increased incidence of tobacco smoking, global warming, geriatric population, emerging markets, new methods for drug discovery, and rise in healthcare expenditure.
The anti-asthmatics and COPD drugs market size is expected to see strong growth in the next few years. It will grow to $107.01 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to the increased popularity of e-cigarettes/ vaping, rising obesity levels, technology, a large pool of undiagnosed population, use of anti-asthmatics and COPD drugs to treat COVID-19 patients, and increasing consumption of fats. Major trends in the forecast period include developing probiotic drugs for asthma, developing anti-il-5 drugs to expand their business portfolio, launching new innovative products to focus on establishing their market position and sustaining their position among the intense competition in the market, investing more in developing bioelectric medicines, focus on increasing the number of collaborations, providing customized treatments, and developing combination drugs to offer better result, developing biologics to capitalize on the growing demand for biologics.
Get Your Free Sample of The Global Anti-Asthmatics And COPD Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3802&type=smp
What are the top drivers to the rising demand in the anti-asthmatics and copd drugs market?
Modifiable risk factors including smoking, lack of physical exercise, and unhealthy eating habits drive the anti-asthmatics and COPD drugs market. Even though there is a decreasing trend in smoking prevalence globally, developing countries such as China, India, Indonesia, and Nigeria among others have increasing smoking prevalence. For instance, the number of tobacco smokers is set to increase by 24 million in Indonesia and by 7 million in Nigeria by 2025, and more than 40% of global cigarette consumption is concentrated in China. Consumption of fats including saturated fatty acids which is a risk factor for Asthma and COPD is higher in high-income countries including the USA and Europe. According to WHO, in developed countries, more than 35% of total energy requirement is derived from fats when compared to <20% in low-income countries, and less than 25% in lower-middle-income countries.
How is the anti-asthmatics and copd drugs market segmented?
The anti-asthmatics and COPD drugs market covered in this report is segmented –
1) By Drug Class: Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, Combination Drugs
2) By Distribution Channel: Hospital Pharmacies, General Pharmacies, Online Retailers
3) By End User: Asthma Patients, COPD Patients
4) By Therapy: Preventive, Curative
5) By Route Of Administration: Oral, Inhaled, Intravenous, Subcutaneous
6) By Age Group: Below 5, 5-14, 15-60, Above 60
Subsegments:
1) By Bronchodilators: Short-Acting Beta-Agonists (SABAs), Long-Acting Beta-Agonists (LABAs), Anticholinergics (Short-Acting And Long-Acting), Methylxanthines
2) By Anti-Inflammatory Drugs: Corticosteroids (Inhaled And Systemic), Leukotriene Modifiers, Phosphodiesterase-4 Inhibitors
3) By Monoclonal Antibodies: Anti-IgE Antibodies, Anti-IL-5 Antibodies, Anti-IL-4 Or IL-13 Antibodies
4) By Combination Drugs: Combination Bronchodilator Inhalers (LABA + LAMA), Inhaled Corticosteroid + Long-Acting Beta-Agonist (ICS + LABA)
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report
Who are the top competitors in the anti-asthmatics and copd drugs market?
Major companies operating in the anti-asthmatics and COPD drugs market include GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Sumitomo Dainippon Pharma Co. Ltd., China National Pharmaceutical Group Co. Ltd. (Sinopharm), Shanghai Acebright Pharmaceuticals Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd, Hanmi Pharmaceutical, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd, Shanghai Anovent Pharma, China Meheco Group Co. Ltd., Lupin Limited, ASGEN Pharmaceutical Co. Ltd, Abbott Laboratories, Pfizer, Vectura Group, Bristol Myers Squibb, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Bayer, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Aspen Nigeria
What significant trends should we anticipate in the anti-asthmatics and copd drugs market over the forecast period?
Major companies operating in the anti-asthmatics and COPD drugs market are innovating new products such as dose combination (FDC) drug, Indacaterol plus Mometasone to increase their profitability in the market. Indacaterol plus Mometasone, delivered via the Breezhaler device, is a once-daily fixed-dose combination (FDC) medication designed for the ongoing management of asthma in patients. For instance, in June 2022, Glenmark Pharmaceuticals, a US-based pharmaceutical company launched a novel-fixed dose combination (FDC) drug, Indacaterol plus Mometasone, for patients suffering from uncontrollable asthma in India. The medication, marketed as Indamet, is offered in three variations, all containing a consistent dose of 150 mcg of Indacaterol and variable doses of Mometasone, which come in 80 mcg, 160 mcg, and 320 mcg strengths.
Which regional trends are influencing the anti-asthmatics and copd drugs market, and which area dominates the industry?
The countries covered in the anti-asthmatics and COPD drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain
What Does The Anti-Asthmatics And COPD Drugs Market Report 2025 Offer?
The anti-asthmatics and copd drugs market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Anti-asthmatic and chronic obstructive pulmonary disease drugs refer to drugs that are used to relieve the frequency of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal awakenings.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3802
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
